{"id":"alprazolam-orally-disintegrating-tablets","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Drowsiness"},{"rate":"15-30","effect":"Dizziness"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Cognitive impairment"},{"rate":null,"effect":"Dependence/withdrawal risk"},{"rate":"5-10","effect":"Ataxia"}]},"_chembl":{"chemblId":"CHEMBL661","moleculeType":"Small molecule","molecularWeight":"308.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alprazolam binds to the benzodiazepine site on GABA-A receptors in the central nervous system, potentiating the inhibitory neurotransmitter GABA. This increases chloride ion influx into neurons, hyperpolarizing the cell membrane and reducing the likelihood of neuronal firing. The result is decreased anxiety, muscle relaxation, and sedation.","oneSentence":"Alprazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:54.790Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders"},{"name":"Panic disorder"},{"name":"Anxiety associated with depression"}]},"trialDetails":[{"nctId":"NCT00139854","phase":"PHASE3","title":"A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-08","conditions":"ANXIETY","enrollment":""},{"nctId":"NCT01188031","phase":"PHASE1","title":"A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-06","conditions":"Healthy","enrollment":40},{"nctId":"NCT01188057","phase":"PHASE1","title":"A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-07","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Alprazolam orally disintegrating tablets","genericName":"Alprazolam orally disintegrating tablets","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alprazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects. Used for Anxiety disorders, Panic disorder, Anxiety associated with depression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}